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LIST	OF	ABBREVIATIONS	
GBM Glioblastoma Multiforme 
OFS l’Office Fédérale de la Statistique 
TP53 53kd-protein acting as a tumor suppressor gene; “genome’s guardian” 
RB Retinoblastoma Protein 
PDGFRA Platelet-derived Growth Factor Receptor, Alpha Polypeptide 
CDKN2A Cyclin-dependent Kinase 2A 
P16 Cyclin-dependent Kinase Inhibitor 2A 
MDM Mouse Double Minute Homolog 
MMP MATRIX metalloprotease 
FGF Fibroblast Growth Factor 
VEGF Vascular Endothelial Growth Factor 
PDGF Platelet-derived Growth Factor 
LOH Loss of Heterozygosity 
PTEN Phosphatase and tensin homologu 
EGFR Epidermal Growth Factor Receptor 
Hif1α  Hypoxia-inducible Factor 1-alpha 
P18 Cyclin-dependent Kinase 4 Inhibitor C 
CDK4 Cyclin-dependent Kinase 4 
Arf Alternate Reading Frame Protein 
IDH1 Isocitrate dehyodrgenase 
PI-3 Kinase Phosphatidyl-inositol-3 Kinase 
MGMT O6-methylguanine DNA methyltransferase 
BT Brain Tumor 
MiR microRNA 
mRNA messengerRNA 
GFAP Glial Fibrillary Acidic Protein 
NES Nestin 
NF1 Neurofibromatosis Type 1 
Akt (PKB) Protein Kinase B 
TNF Tumor Necrosis Factor 
NF-κB Nuclear factor Kappa-light-chain-enhancer of activated B cells 
MERTK Proto-conogene tyrosine—protein kinase MER 
CHI3L1 Chitinase-3-like protein 1 
MET (HGFR) Hepatocyte Growth Factor Recepto 
PIK3CA:  phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha 
SOX Superfamily of genes related to SRY (Sex determing Region on Y) 
DCX Doublecortin protein encoded by the gene DCX 
DLL3 Delta-Like 3 
ASCL1 Achaete-scute Homolog 1 
TCF4 Transcription Factor 4 
NKX2-2 Transcription factor involved in morphogenesis of the nervous system 
OLIG2 Oligodendrocytes transcription factor 
P21 (CDKN1A) Cyclin-dependent Kinase Inhibitor 1A 
NEFL Neurofilament Light Polypeptide 
GABRA1 Gamma-Aminobutyric Acid Receptor Alpha1 
SYT1 Synaptotagmin 1 
SLC12A5 Solute carrier family 12 (K1/Cl- transporter), member 5 
WHO World Health Organization 
Ki-67 Antigen for proliferation. Kiel (Germany), 96-well plate 67 
	 3	
LIST	OF	ABBREVIATIONS	(2)	
MIB-1 Antigen for proliferation 
Gy Gray 
CCNU Lomustine, chemotherapy 
GSC Glioma Stem Cells 
CD133 cluster of differentiation 133 
LCAM1 L1 Adhesion Molecule 
SSEA-1 Stage-specific embryonic antigen 1 
CXCL12 chemokine (C-X-C motif) ligand 1 
CXCR4 C-X-C chemokine receptor type 4 
NSAID Non-Steroidal Anti-Inflamatory Drugs  
UTR Untranslated Region 
Pri-miR Primary microRNA 
Pre-miR Precursor microRNA 
DGCR8 DiGeroge Syndrome Chromosomal Region 8 
dsRNA Double-Stranded RNA 
RISC RNA-induced silencing complex 
AGO Agonaut 
XPO5 Exportin5 
ATM Ataxia Telangiectasia Mutated 
C. Elegans Caenorhabditis Elegans 
SMAD “Mothers Aganais Decapentaplegic” + SMA in C. Elegans 
TGFβ  Transforming Growth Factor Beta 
BMP Bone Morphogenetic Protein 
TRBP TAR (transactivation response) RNA-Binding Protein 
r-SBE TGFβ/BMP-regulated miRNA consensus sequence 
Oct4 Octamen Binding Transcription factor 4 
Nanog From Scottish “Tìr na nÒg Legend” meaning “Land of Youth” 
TMEM49 Transmembrane Protein 49  
RECK Matrix metalloprotease regulator 
TIMP3  Tissue Metallopeptidase Inhibitor 3 
IGFBP3 Insulin-Like Growth Factor-Binding Protein 3 
Bax Bcl-2-like-Protein 4 
Bcl-2 B-cell Lymphoma 2  
NOD-SCID commonγKO Non-Obese Diabetic, Severe Combined Immunodeficiency, Knock-Out 
LNA Lockec Nucleid Acid 
BRDU 5-bromo-2’-deoxyuridine 
SVZ Subventricular Zone 
Scr-Ctrl Scrambled Control 
FASLG Fas (transmembrane protein) Ligand 
GFP Green Fluorescent Protein 
IRB Institutional Review Board 
PenStrep Penicillin Streptomycin 
NEAA Non-Essential Amino Acid 
FCS Fetal Calf Serum 
M-MLV Moloney Murine Leukemia Virus 
PPIA Peptidylprolyl Isomerase A (Cyclophilin A) 
SNORD49a Small Nulceolar RNA, C/D Box 49A 
ACK Ammonium-Chloride-Potassium 
HEK Human Embryonic Kidney 
CMV Cytomegalovirus 
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1.	INTRODUCTION		
1.1	BACKGROUND	ON	GLIOBLASTOMA		1.1.1	EPIDEMIOLOGY	
Cerebral tumors account for 1-2% of all cancers in Switzerland(1)(2). 58% of primary brain tumors 
are gliomas (1). Of the 500-700 (2) persons suffering from gliomas each year in Switzerland, 250-
300(3) have glioblastoma multiforme (GBM), which makes it the most common type of malignant 
primary brain tumor in adults, whereas cerebral metastases represent the majority of all brain 
tumors (4). Caucasian males living in industrial areas are believed to be most often affected by 
GBM (5)(6). Despite its controversial role in GBM pathogenesis, l’Office Fédéral de la Statistique 
(OFS) recommends limiting radiation from cell phone use (1).  1.1.2	CLINICAL	MANIFESTATIONS	
Clinical manifestations of GBM are variable — depending on the tumor’s localization and rate of 
progression — and span a range of diverse signs and symptoms. However, the first manifestation 
of GBM is often a seizure, accompanied by a long-lasting atypical headache and a focal 
neurological deficit (7). General symptoms, such as nausea, vomiting, and loss of appetite, 
caused by increased intracranial pressure due to the tumor’s mass surrounded by oedema are 
common (1). GBM rarely metastatizes, even though spreading through the subarachnoidal space 
to the spinal cord can occur (7). Its principal location is in the subcortical hemispheres, involving 
white matter (7) and, typically, fronto-temporal location is a predilection site (8). Clinical history is 
usually short, less than three months in 50% of patients affected by de novo GBM. However, 
secondary GBM, which accounts for 40% of cases (9) and  arises from grade II or III gliomas, may 
have subtle manifestations for one-to-ten years before being diagnosed. It is often impossible to 
distinguish between a benign lesion and a malignant tumor based on the clinical history alone 
(10). 1.1.3	PATHOGENESIS	
HISTOLOGY 
Glia, the neuronal support tissue can occasionally give rise to gliomas, which are divided into 
astrocytomas, oligodendrogliomas or ependymomas, depending on the cell of origin. Gliomas are 
categorized into four different grades, whose characteristics are summarized in Figure 1. Notably, 
GBM defines grade IV astrocytomas and is the most aggressive type of glioma.  
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 Cell of origin Grade Name Macroscopy (7) Microscopy (7) Survival rate (2) 
No
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I 
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cy
tic
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cy
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a Cystic 
predominantly 
Bipolar cells with GFAP+ 
processes, Rosenthal 
fibers, eosinophilic 
granular bodies, necrosis 
and mitoses are 
uncommon 
Forseeable 
recovery if total 
resection 
II 
Di
ffu
se
 
As
tro
cy
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m
a Poorly defined, gray, infiltrative, 
cystic 
degeneration may 
be present 
Increased glial cellularity, 
variable nuclear pleo-
morphism, GFAP+ 
astrocytes processes-> 
fibrillary aspect 
7-10y 
II 
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More densely cellular, 
more nuclear 
pleomorphism 
3,5y 
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g IV 
Gl
io
bl
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a 
Variation is 
specific: 
firm/white, 
soft/yellow/necroti
c, cyst and even 
hemorrage 
Similar to anaplastic 
+endothelial proliferation 
(double layer, 
glomeruloid body), 
pseudopalisades 
surrounding necrosis 
Methylated: 23m 
Non-methylated: 
13m 
Lower 
grade 
Often II/IV  
Well-
circumbscribed, 
gelatinous, gray 
+cysts, 
hemorrhage, 
calcification 
Regular cells with 
spheroical nuclei with 
finely granular chromatin 
Perineuronal satellitosis 
Ol
ig
od
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ig
od
en
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Higher 
grade 
Often 
III/IV 
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Increased cellular 
density, nuclear 
anaplasia, increased 
mitotic activity, necrosis, 
confusable with GBM 
5-10y 
Ep
en
dy
m
om
a 
Ep
en
dy
m
al 
ce
lls
 
Several names 
depending on the 
location 
Solid or papillary 
masses 
Regular, round/oval 
nuclei, abundant granular 
chromatin, perivascular 
pseudorosettes, GFAP+ 
20-30% à 5ans 
(11) 
 
Figure 1: Classification and description of gliomas (12) 
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SIGNALING PATHWAYS 
The majority of GBMs are believed to develop sporadically, though specific genetic alterations are 
progressively coming to light. Transformation of a permissive cell by one of several possible 
oncogenic events provides growth and survival advantage that lead to the emergence of a clone, 
which retains the features of the initial transformed cell. The clone then progressively evolves into 
a heterogeneous tumor mass through a combination of genetic and epigenetic modifications. The 
cell of origin of GBM remains unidentified although adult neural progenitor and mature glial cells 
are proposed to be plausible candidates (13). 
In GBM, TP53, RB and 
receptor tyrosine kinase 
pathways are commonly 
altered (10). Lower grade 
astrocytomas are associated 
with mutation of TP53, which 
hinders DNA repair, and 
overexpression of PDGFRA. 
Transition to a higher grade 
ordinarily implies deletion or 
suppression of two tumor 
suppressor genes 
p16/CDKN2a and RB (7) along 
with dysregulation of MDM2, 
MDM4 and MMP9 expression 
and the upregulation of 
several growth factors such 
as FGF, VEGF and PDGF1. 
Interestingly, mutation and 
dysregulation of Ras and 
PDGFβ lead to 
oligodendroglioma 
development (13).  
 
Major events in GBM tumorigenesis are (13):  
• Differentiation: Tumor progenitor cells show phenotypic properties of either astrocytoma 
or oligodendroglioma depending on the oncogenic hits on one hand and the 
microenvironment on the other, leading to expression of neural and glial markers and 
involving different pathways. Commonly, dysregulation of p53 leads to an astrocytoma, 
whereas oligodendrogliomas display chromosome 1p19q translocation.  
• Necrosis/hypoxia: Highly malignant tumors have high metabolic demand. Nevertheless, 
intratumoral vasculature is leaky and inclined to develop thrombosis, leading to hypoxia 
and central necrosis. Hypoxia activates Hif1α, which increases migration and gelatinase 
activity, as well as secretion of growth factors. This state selects apoptotic resistant tumor 
cells bearing inactive p53, which appear to be more aggressive, heterogenous and 
resistant to cytotoxic therapies. 
• Angiogenesis: Microvascular proliferation occurs via VEGF, leading to proliferation of 
endothelial and smooth muscle cells and formation of glomeruloid vessels. These 
structures are irregularly distributed, in a semi-circular pattern around necrotic foci and 
sometimes at invasive edges. VEGF and PDGR secretion can participate in the breakdown 
of the blood/brain-barrier, leading to increased permeability and therefore oedema. 
• Invasion occurs by exhibiting, on a histopathological level, secondary structures of 
Scherer, which affect white matter. Sometimes butterfly aspects arise involving both 
hemispheres, but perineuronal, subglial and perivascular spaces are engaged. Key 
functions deregulated are: cell adhesion, motility in the extracellular matrix and signal 
Figure 2: Time and frequency of genetic alterations during 
astrocytoma progression. Reproduced from (9)	
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transduction pathways. Brain matrix consists of mostly hyaluronic acid, with basal lamina 
in perivascular regions. Effector molecules implicated include metalloproteases, such as 
MMP2 and MMP9, integrins and growth factors including FGF, EGF and VEGF. 
Amplification of EGFR pathways is found in cells on the infiltrative edges and is believed to 
play a role in recurrence. 
• Tumor progression: In 50% of GBM, the cell cycle is deregulated by involvement of p18, 
CDK4, CDK6, cyclinD1 and Rb. The other 50%, CDKN2A, which encodes p16 and Arf 
proteins, is homologously deleted, mutated or hypermethylated. Primary GBMs that show 
aggressive outcome, harbor amplification of MDM2 and aberrant forms of EGFR, such as 
EGFRvIII (mutated form lacking exons 2-7) or v-ErbB (present in 30% of GBM) and display 
loss of PTEN (14). On the other hand, secondary GBM usually have p53 mutated, loss of 
chromosome 19q (14) and increased signaling via PDGFRA. IDH1 mutations also occur in 
a majority of secondary GBM (14). Nonetheless, both pathogenic pathways lead to 
activation of RAS and PI-3 kinase, as well as increased receptor tyrosine kinase activity, 
that result in tumor growth (7). Loss of 1p and 19q chromosomes, which are typically 
signatures for an oligodendroglial phenotype, have been found in a considerable fraction 
of GBMs that have a better survival rate (22.2m vs. 13m) (12).   
 
MOLECULAR SUBTYPES 
When focusing on pathogenesis on a transcriptome level, GBM is divided into 4 different classes: 
classical, proneural, neural and mesenchymal. Each category’s specificities are compiled in 
Figure 3. Customarily, there is no switching between subclasses when recurrence of GBM 
occurs. Additionally, no association has been made regarding the DNA repair gene MGMT’s 
methylation, which is an important prognostic factor, and subtypes (15). Brain Tumors (BT) 4, 8 
and 11, all primary cell cultures that we have used, have been classified as proneural GBM cells 
after RNA-seq analysis. 
Classification based on microRNA (miR) expression profiles appears to be even more precise than 
that based on messengerRNA (mRNA) expression. On this basis, five GBM clusters have been 
identified and are correlated to different clinical outcomes. Thus, expression of miR196a/b, 
among 10 other miRs, is associated with shorter overall survival (16). MiR expression profiles have 
not only been used to differentiate GBM from anaplastic gliomas, but have enabled us to identify 
these 5 subclasses of GBM (17). However physical interactions between miRs and mRNAs have 
to be better understood in order to gain in classification precision. 
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Subtype Genetic alterations 
Possible 
progenitor 
cell 
Survival 
(months) 
Clinical 
specificity 
Mean 
age 
MiR 
identification 
(18) 
Cl
as
sic
al
 
Chr7 ampl, loss of chr10, 
lack of  TP53 mut, 
Ink4a/ARF del,  
EGFR ampl + alt  
If EGFR ampl, Rb pathway 
altered via CDKN2A del  
Notch, Sonic hedgehog 
pathways and neural 
precursor and stem cell 
marker NES highly 
expressed  
Astrocytic  
signature 12.2 
More advantage 
regarding mortality if 
treated aggressively 
* 
55.7 
Risky : 
miR26a, miR767, 
miR153, miR31, 
miR22 
Protective : 
miR654, miR422b 
M
es
en
ch
ym
al
 
NF1 del + mut + co-mut 
with PTEN interfering on 
AKT pathway  
TNF and NK-κB pathway 
highly expressed  
EMT due to higher activity 
of mesenchymal and 
astrocytic markers such 
as CD44 and MERTK    
Mesenchymal CHI3L1 and 
MET, Swann cell S100A, 
as well as microglial 
markers expressed 
Astroglial + 
microglial 
signature 
11.8 
Higher necrosis rate 
and inflammatory 
infiltrates  More 
advantage regarding 
mortality if treated 
aggressively *  Link 
via NF1 with 
neurofibromas ?  
57.7 
Risky : 
miR373, miR296, 
miR191 ,miR602 
Protective : 
miR223  
Pr
on
eu
ra
l 
IDH1 mutation or 
PDGFRA ampl + mut in 
Ig-domain, TP53 mut 
+LOH  
If no PDGFRA 
abnormality, 
PIK3CA/PIK2R1 mutated  
High expression of 
proneural development 
genes: SOX, DCX, DLL3, 
ASCL1 and TCF4  
High expression of 
oligodendrocytic genes: 
PDGFRA, NKX2-2, 
OLIG2.  
OLIG2 downregulates p21 
and, thereby, CDKN1A   
Oligodendrocytic 
signature 11.3 
No use of 
aggressive* 
treatment  
More inclined to 
recurrence  
Possibly 
secondary** GBM   
Resemblance with 
oligodendro-
gliomas  
51.8 
Risky :  
miR582 
Protective : 
miR130, miR195 
NonG-CIMP 
Risky : 
miR335, miR34a, 
miR581, miR21 
Protective : 
miR361, miR145, 
miR143, miR378, 
miR182, miR183 
Ne
ur
al
 Neuron markers NEFL, 
GABRA1, SYT1, SLC12A5 
characteristic 
Oligodendrocytic 
and astrocytic  
Neurons 
13.1 
Similar expression 
pattern with normal 
brain tissue 
63.8 
Risky : 
miR222 
Protective : 
miR422a, 
miR662, miR566, 
miR24, miR370, 
miR492, miR629 
 
Figure 3: Molecular description of GBM subtypes. Genes in bold are those defining each category (15). 
*Aggressive stands for either a concurrent radiochemotherapy or at least three subsequent chemotherapy 
cycles ** stemming from grade II or III glioma. Ampl = amplification, chr = chromosome, alt = alteration, del 
= deletion, mut = mutation, EMT= epithelial-to-mesenchymal transition, LOH = loss of heterozygosity 
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1.1.4	DIAGNOSIS	
Definite diagnosis is confirmed after histopathological confirmation. Strong clinical suspicion, 
supported by radiological findings will encourage a stereotaxic biopsy or even resection. Usually 
fresh frozen sections are performed intra-operatively to guide the neurosurgeon in the sampling 
and give the most accurate intra-operative diagnostic interpretation. Cytopathology, 
immunohistochemistry and genetic assessment are the most employed tools to determine 
precisely the lesion’s nature and, in the case of a glioma, grade it according to the World Health 
Organization (WHO) classification (12). Usually hematoxylin and eosin stains are used in 
histopathology, glial fibrillary acidic protein (GFAP) and cytokeratin are relevant markers and Ki-
67/MIB-1 help determine the cell proliferation rate. Expression of GFAP is usually associated with 
astrocytic tumors, whereas loss of 1p and 19q chromosomes underlies oligodendroglial 
phenotypes (19). Unfortunately, despite establishment of precise criteria, inter- (20) and intra-
tumoral (21)(22) heterogeneity of GBM renders classification challenging. Thus, an important 
debate is still ongoing about how to name a glioblastoma with oligodendroglial component; 
“oligoastroyctoma WHO grade IV” or “oligodendroglial glioblastoma multiforme”. Nevertheless 
prognosis is mostly affected by the presence of necrotic foci (23). This explains the constant 
reorganization through regular consensus such as the StAnne/Mayo classification and regular 
updates by the WHO, the latest dating from 2007; not only are classifications reshuffled, but 
additional entities keep being added (ref. appendix). As glioma progression is driven through 
acquisition of additional genetic mutations as well as epigenetic modification, it is no surprise to 
find that analysis of different subpopulations of GBM cells reveals not only genomic variability, but 
also heterogeneity at the transcriptome, microRNAome and methylome levels (14). This renders 
definition of the cell of origin all the more challenging. A biopsy is therefore rarely representative 
of the entire tumor but rather constitutes no more than a temporo-spatial snapshot of the lesion. 
GBM heterogeneity can be such, that one could almost assume the presence of different tumors 
within the same mass (24). 1.1.5	TREATMENT	
In 1884, the first brain tumor was surgically excised by hemispherectomy (14). Currently, standard 
treatment of GBM includes total or subtotal surgical resection, followed by adjuvant radiation and 
chemotherapy. Even though it reduces the mass effect and therefore intracranial pressure, 
surgery alone is unfortunately not sufficient due to GBM’s infiltrative nature, hence the need for 
adjuvant therapy (25). 
RADIO-CHEMOTHERAPY 
When employing radiotherapy, 60Gray (Gy) are usually delivered in 2Gy doses to the tumor 
surface with a 2-3cm margin. This option decreases irradiation of normal tissue and consequently 
avoids neurocognitive toxicity, leukoencephalopathy and endocrinopathies (26). Brachytherapy 
has shown no beneficial effect (27). Regarding chemotherapy, there is a wide range of available 
drugs, which we are not going to detail here. However, temolozomide has helped extend survival 
since its introduction in 2013 (2). Symptomatic therapies such as antalgia and anticonvulsants 
play an important role in GBM patient management (1). 
PERSONALIZED TREATMENT 
Since GBM displays wide heterogeneity in genomic and phenotypic properties, personalized 
treatment may be applicable. However, in order to do so, more precise classification, leading to 
more specific drugs, is necessary. Subtype specific drugs showed inhibitory effects on the in vitro 
clonogenicity of patient derived cells and decreased their resistance to temolozomide (28).  
Activation of EGFR receptor leads to downstream activation of the PI-3K/AKT pathway, which 
promotes cell survival, proliferation and infiltration. Blocking EGFR with erlotinib and gefitinib, two 
small molecule kinase inhibitors, have shown some temporarily promising effects, yet rapid 
resistance to treatment due to compensatory expression of adjacent EGFR receptors, such as 
ERBB2 and ERBB3 has been observed to occur. Lapatinib, another inhibitor, which blocks EGFR 
and ERBB2, caused reduction of AKT expression, but therapy resistance appeared over time. 
Erlotinib and gefitinib had some beneficial effect when EGFRvIII and PTEN are co-expressed (12). 
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Loss of chromosome 1p has been correlated with a positive response to procarbazine, CCNU 
and vincristine. When chromosome 1p/19q are lost, longer survival and response to 
temolozomide have been observed (13). 
RECURRENCE 
Recurrence, which is common in GBM, is 
believed to be driven by cancer stem cells, 
which show resistance to chemo and 
radiotherapy (29). Becavizumab, an anti-
VEGF antibody, has shown clinical benefits 
when combined with Irinotecan in recurrent 
GBM (30). Curiously, although EGFRvIII 
increases proliferation and promotes anti-
apoptotic signaling it is associated with 
better prognosis and lower recurrence. In the 
absence of EGFRvIII, the tumor appears to 
be resistant to temolozomide (14). 
PROGNOSIS 
Prognosis is affected by age, neurologic 
impairment, localization, radiological features 
(contrast enhancement), surgical resection 
extent, proliferation index and genetic 
features (23). 
A predictive factor for an early response to 
combined radio- and chemotherapy is the 
presence of silencing by hypermethylation of 
the MGMT gene promoter, which does not 
allow alkylation of the O6 guanine and 
inhibits DNA repair proteins. It is associated with relatively favorable response to temolozomide 
therapy (12) with survival for up to 21.7months (vs. 12.7m). Hypermethylation of the MGMT 
promoter is found in up to 40% of GBM (19) and seems exclusive to the classical subtype (14). 
Prognostic factors: EGFR(9), deletion of chromosome 1p/19q (19), IDH1 (14) 
Predictive factors: age(9), hypermethylation of MGMT (19), combination with IDH1 (14), 
presence of miR21 (31) 
Survival rates are 42.4% at 6 months, 17.7% at one year and 3.3% at 2 years (32) with a mean 
age for GBM to appear at 53years (9).  1.1.6	GLIOMA	CANCER	STEM	CELLS	
As indicated previously, fatal relapse is believed to be driven by a sub-population of cells called 
glioma stem cells (GSC) (33), which display self-renewal properties, multi-lineage plasticity and 
tumor initiating capacity in xenografts generating tumors that phenocopy the tumor of origin. They 
are believed to occupy the top of the cell differentiation hierarchy, losing their self-renewal and 
tumorigenic capacities the further they advance through differentiation. They initiate tumors, are 
responsible for recurrence and metastasis and are more chemoradioresistant than their more 
differentiated progeny (34)(35). Recurrence occurs with a higher density of GSC and their 
presence predicts more somber prognosis. VEGF can be GSC-associated and promotes 
angiogenesis, hemorrhage and invasion. Also GSC are often found in vascular niches (35).  
Better recognition and isolation of these cells will lead to improved patient survival by targeting 
therapies to GSC, sparing normal tissue. In mouse models of gliomas, specific targeting of the 
GSC population has been shown to prolong survival by limiting relapse rates (34). It is to be 
noticed that any type of therapy changes cell markers and expression profiles, making the task to 
identify GSC trickier after therapeutic agents have been applied (29). CD133, Sox2, Musashi and 
Figure 4: Prognostic outcome of four molecular 
subtypes of 105 GBM patients. Reproduced from (28) 
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Nestin are recognized markers for GSC identification. One of the first identified markers on cells 
that mimic neural stem cells is CD133. As clones undergo asymmetric division, both CD133 + and 
- cells are present in tumor bulks. The positive fraction is better known to be more tumorigenic, 
however, the negative fraction can reform tumorigenic cells and even divide again into cells 
carrying CD133, resulting in the idea that CD133 expression and stemness features are reversible 
and microenvironmentally adaptable processes (14). CD133 still remains the most satisfying 
marker since 60% of freshly resected GBM express it. Other identification markers have been 
suggested such as LCAM1, SSEA-1, A2B5, Integrin6, Nestin and Aldehyde Dehydrogenase1 but 
not with a reproducibly successful rate (36). 
GSC can be grown and expanded as floating spheroids under serum free conditions and are 
commonly referred to as gliospheres. Exposure of GSC to serum triggers profound epigenetic 
changes leading to adhesion to substrate in vitro, expression of markers of differentiation, loss of 
clonogenicity in vitro and tumorigenicity in vivo (37). 
In vivo it has been observed that GSC escape from the tumor mass to migrate to the 
subventricular zone after transplantation, where they find self-renewal niches. In this migration 
process, CXCL12 and CXCR4 are possibly implicated (38). 
Despite the fact that gliospheres and adherent GBM cells share the same genetic background, 
their major phenotypic differences and capacity to initiate tumor growth is the result of epigenetic 
changes. Epigenetic mechanisms involve long non-coding RNAs (40), chromatin-based 
mechanism (41) and miRs, the latest playing an important role in stemness as described below 
(42)(43). Chromatin state, with the action of transcription factors and chromatin regulators, 
additionally to its pre-existing state (methylation, acetylation, etc.), guides as well stemness (39). 
1.2	MICRORNAS	
MiRs are small non-coding RNA molecules consisting of about 22 nucleotides. In their sequence, 
miRs contain a seed sequence of about 2-7nucleotides long, which binds to complementary 
sequences primarily within the 3’UTR of targeted mRNA and leads to their degradation or 
translational repression, depending on the level of complementarity. Subsequently, they operate 
as negative regulators of protein production and are therefore crucial repressors of gene 
expression. As they are involved in almost every biological process – including metabolism, 
ageing, development - they participate toward providing homeostasis in normal tissues. However, 
this seemingly robust system can undergo dysregulation, one consequence of which may be 
transformation and tumorigenesis (44).  1.2.1	MIRS	IN	TUMORIGENESIS	
They are several ways for miRs to be involved in tumorigenesis: 
1. MiRs control expression of tumour suppressor genes. Targeting them leads to their 
repression and thus loss of their protective capacities. These miRs are called oncomirs;  
2. Anti-oncomirs are miRs repressing oncogene mRNA, therefore they act as tumor 
suppressors. Any mechanism that downregulates these miRs (via silencing or deregulation 
in their maturation pathway) can contribute to malignancy (45); 
3. Evidently, any isolated mutation in either the seed region or in the 3’UTR engenders loss of 
complementariy between these two regions and consequently loss of function of specific 
miRs; 
4. MiRs go through complex processing steps any of which may be deregulated; 
5. Ribonucleotide binding proteins (RBP) may bind to or in the vicinity of miR binging sites on 
their target transcripts, regulating their effect on target gene degradation. Changes in their 
expression, activity, abundance or affinity for miR binding sites may lead to transformation 
(46); 
Generally, downregulation of all miRs has shown promotion of disease suggesting that overall 
tumor-suppressive function of miR is more important than its oncogenic ability. The cluster miR-
17-92 is highly prevalent in a wide range of cancers and induced expression of these miRs 
promotes cancer (47). 
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1.2.2	MIRS	MATURATION	PATHWAY	
According to reviews (16)(48)(49), after being transcripted by the RNApolymerase II, primary-miRs 
(pri-miR) are processed into precursor-miR (pre-miR) by a Microprocessor complex; the key 
components of this complex consist of DROSHA, an RNA III enzyme, and DGCR8, a dsRNA-
binding protein Then, pre-miRs are exported out of the nucleus by Exportin-5, which is Ran-GTP-
dependent. Once in the 
cytoplasm, a multiprotein Dicer 
complex generates from the 
70nt pre-miR a 21-23 mature 
miR. This double-stranded 
mature miR is then separated: 
one strand is loaded onto the 
RNA-induced silencing 
complex (RISC) by an 
Argonaut (AGO) protein, with 
the GW182 protein, whereas 
the other strand is degraded. 
Once attached to the complex 
RISC, miRs find their target 
transcripts and bind to their 
complementary sequence by 
their seed sequence within the 
3’UTR, thereby inducing 
mRNA degradation or 
translation blockade. 
Sometimes a bi-functional pair 
of miRs, such as miR9/9*, exist 
where both miR strands have 
an inhibitory function (50). In rare cases, miRs, by binding to 5’ UTR, enhance expression of 
different mRNAs (31). Since one miR corresponds to several complementary sequences on 
mRNAs, a small number of miRs can regulate a large repertoire of genes. Over 1’500 precursors 
and over 1900 mature Homo sapiens miRs have been reported in the miRBase so far (16).  
As discussed previously, several steps in the maturation process can be dysregulated: 
1. Compartmentalization has been shown to control the maturation pathway by 
concentrating cofactors, isolating processes in specific cellular microenvironments and 
therefore facilitating interaction with binding partners (51); 
2. One of the crucial steps in miR biogenesis is exportation of pre-miRs outside the nucleus 
via Exportin 5 (XPO5), a specific karyopherin. If mutations occur in the XPO5 gene, pre-
miRs are retained in the nucleus and processing by Dicer and TRBP does not (49)occur, 
which has been associated with tumorigenesis. Homozygous mutations in XPO5 are lethal 
events in cancer cells. It has been noticed that additional nuclear export pathway exist in 
C. elegans and that exportation is accelerated when DNA damage is present in an ATM-
dependent manner (51)(52); 
3. Stimulation of migration and metastasis happens when low Dicer processing occurs (53) 
(54); 
4. SMAD (signal transducer of TGFβ and BMP) promotes expression of miRs by inducing the 
cleavage reaction by Drosha. T/B-miRs (miRs regulated via TGFβ) such as miR21 and 
miR199a among 20 others, contain an R-SBE domain in their stem region of their pri-miR 
form, which is bound by SMAD and regulated via TGFβ and BMP (55); 
5. Ultimately, it has been shown that some miRs act in the nucleus by binding to promoter of 
specific genes and inducing their repression (51); 
Figure 5: MiR biogenesis. Reproduced from (45) 
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1.2.3	MIRS	IN	STEMNESS	
MiRs play a crucial role in generation, maintenance and differentiation of stemness, rendering 
them attractive toward the development of stem cell therapies. One of the most notable examples 
is one of the first miR discovered: let-7. The let-7 family is involved in development and has been 
extensively studied in the development of C. elegans through sequential heterochronic gene 
expression, meaning that if a mutation occurs, development stops at a defined developmental 
stage. Due to its lack of AUG in an open reading frame, it is never transcribed, neither is it spliced 
due to its unsuitable size. It is complementary to the 3’UTR of heterochronic genes lin-14, lin-28, 
lin-41, lin-42 and daf-12. Let-7 and lin-4 both regulate by their RNA lin-14 and lin-28 through 
RNA-RNA interactions via 3’UTR and so coordinate developmental timing at different stages (56). 
The let-7 family consists of 4 members in C. elegans and 15 in humans. In humans, processing of 
several pri-miRNAs is blocked when cells are in an embryonic state. Once time for differentiation 
occurs, this blockade resolves and expression occurs. Expression of mature let-7 miR has been 
shown to be decreased in embryonic cells compared to differentiated cells, whereas pre-miR let-
7 remains at a constant level. This is due to lin-28 specifically blocking the maturation process at 
the Microprocessor step (57). Lin-28a and lin-28b act as posttranscriptional repressors of pre-let-
7 in the cytoplasm by inducing its degradation via terminal uridylation at its 3’end and therefore 
blocking Dicer-mediated processing. It is not very clear whether this occurs in the Drosha step or 
the Dicer processing step (47). Since let-7 is involved in differentiation, lin-28 enables stemness 
maintenance and tumorigenesis. There is a double negative looping feedback between lin-28 and 
let-7 (58). In summary, let-7 acts as an anti-stemness and proliferation factor, whereas lin-28 
favors stemness. (59). In combination with Oct4, Nanog and Sox2, lin28 can reprogram 
pluripotency in fibroblasts, leading to induced pluripotent stem cell (iPSC) formation (57). 
Due to their important role in stemness, it seems reasonable to propose that miRs are also 
involved in cancer stem cell establishment and maintenance. Establishment of tumor-associated 
miR expression repertoires may help develop miR-based targeted therapies aimed at rectifying 
miR dysregulation in GSC (16). 1.2.4	MIRS	&	THERAPY	
New therapies including targeted, antiangiogenic, and cancer stem cell-specific therapies as well 
as specific vaccines are being developed, bringing hope to this currently incurable disease (1). 
Regarding miRs, targeted therapies follow two axes: inhibition of oncogenic miRs or replacement 
of tumor-suppressive miRs. Replacement therapies appear to be more practically feasible, and 
some potentially promising results have been obtained with miR34 (60). However, progress has to 
be achieved on the delivery system, especially with respect to overcoming the Blood/Brain 
barrier. Using the non-metastatic property of GBM for local delivery might be an option. Some 
new insights in molecular therapies have been shed, since the discovery of intercellular 
communication via secreted functional miRs. This suggests that regulation of aberrant miR 
expression may enhance chemo- and/or radiotherapy sensitivity, as well as responsiveness to 
molecular-targeted therapy (61). 													
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1.2.5	MIR21	
MiR21 is involved in several processes: development; cancer; cardiovascular and pulmonary 
diseases; and inflammation. It is located in the TMEM49 gene and is transcribed independently 
due to its own promoter (62). Regarding oncogenesis, miR21 is overexpressed in 6 solid cancer 
types (62) where it plays an anti-apoptotic role (63). The concept of oncomiR addiction has 
arisen ; namely dysregulation of miR21 appears to be necessary for initiation and/or maintenance 
of the malignant state (62). Using microarrays and qPCR, several studies (63)(64) identified miR21 
(with miR10b, miR128-1 and miR128-2) as a recurrent aberrant miR in GBM pathogenesis, 
present in up to 44-100% of GBM (31). Its presence is correlated with more aggressive clinical 
outcome and worse prognosis (65). When miR21 is suppressed, decreased cell growth, increased 
apoptosis, reduced invasiveness and reduced tumorigenecity (via upregulation of tumor 
suppressor genes such as p53) have been observed. Its role in invasiveness is linked to its 
interaction with MMP inhibitors RECK and TIMP3. When looking at targets, TGFβ, p53 and 
mitochondrial initiated apoptosis pathways are implicated (31). One of the direct targets is 
IGFBP3 which acts as a tumor suppressor gene and inhibits gliomagenesis; overexpression of 
IGFBP3 occurs with inhibiton of cell proliferation in vitro and tumor formation in vivo when miR21 
is suppressed (66). Recent studies have shown that aberrant miR expression, such as miR21, has 
been correlated to radiation and chemotherapy resistance, especially temolozomide. 
Overexpression of miR21 inhibits TMZ-induced apoptosis via Bax/Bcl-2 (67)(68). Mir21 has also 
been shown to play a crucial role in radiosensitivity via the Pi3K/AKT pathway and by modulating 
tumor suppressor networks (69)(70). Therefore miR21 may provide an attractive target to 
modulate. Some groups have started measuring it in different biological fluids for correlation with 
clinical behavior and outcome (62). Baraniskin et al. correlated detection by qPCR of miR21 in the 
cerebrospinal fluid with the presence of gliomas (71)		
2.	AIMS	
 
The aims of this project are to: 
• Assess miR expression profile of freshly resected GBM GSC vs. tumor bulk, sorted by 
magnetic separation for CD133 marker expression 
• Select and validate by qPCR miRs whose expression is markedly different in CD133+ vs. 
CD133- cell fractions 
• Determine whether a subset of differentially expressed miRs are maintained in vitro in cells 
cultured as spheres or adherent monolayers that represent the GSC and tumor bulk 
fractions, respectively 
• Modulate miR21 expression in primary GBM spheres by infection 
• Evaluate the effect of miR21 overexpression on proliferation and clonogenic capacity of 
spheres in vitro ± in vivo by injection of control or miR modulated cells into NOD-SCID 
common γKO mice 
• Potentially, identify and validate mRNAs targeted by miR21 
2.1	EXPECTED	RESULTS	
Results of this study should allow us to identify miRs that are differentially expressed in GSC vs. 
GBM tumor bulk, either in freshly removed tumors sorted for CD133+ cell subpopulations or in 
vitro under culture conditions that maintain GSC (spheres) or induce differentiation (adherent 
cells). We expect to select a subset of miRs whose expression is specifically altered in the GSC 
fraction. The phenotype of cells overexpressing miR21 will be assessed. We expect to find 
differences in clonogenic, proliferation and tumor initiating capacities upon modulation of 
expression of miR21. Depending on the results obtained and schedule, we plan to seek mRNA 
transcripts specifically targeted by differentially expressed miR21 in GSC compared to their 
differentiated counterparts and that consequently contribute to maintaining the phenotype of this 
highly malignant cell population. 
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3.	RESULTS	
 
3.1	IDENTIFICATION	OF	MIRS	EXPRESSED	IN	PRIMARY	GLIOBLASTOMA	CELL	LINES	IN	VITRO	
In order to establish the expression profile of miRs in primary GBM, we extracted RNA from three 
primary GBM cell lines (namely BT4, 8 and 11), which were grown as spheroids or adherent cell 
monolayers. Gliospheres are maintained and expanded under serum free conditions and stand as 
a model for GSC. Upon exposure to serum, GSC become adherent, undergo dramatic epigenetic 
reprogramming and lose their tumorigenic potential (37) (72). We performed a microRNA-array in 
order to compare the expression profile of glioma-stem-like cells vs. differentiated adherent 
counterparts. A scatterplot in Figure 6 illustrates the top differentially expressed miRs in both 
culture conditions. MiR21, which will be of interest later, was surprisingly shown to be one of the 
top downregulated miRs in GSC, compared to adherent cells.  
Interestingly, GSC expressed high levels of miR9, which was previously shown to be a critical 
regulator of neurogenesis and differentiation (73). MiR340 was recently reported to act as a tumor 
supressor miR in GBM (74). However, we observed that miR340 was upregulated in the GSC 
fraction. 
Figure 6: miRNAarray operated on RNA extracted from three GBM cell lines 
BT : brain tumor, X : primary tumor number, A : adherent culture conditions, S : sphere culture conditions  
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To confirm the observations of the microRNAarray, we performed qPCR with specific LNA (locked 
nucleic acid) primers, which showed consistent results with high-troughput analysis. MiR21, 
miR221 and miR335 are significantly downregulated in all tumors grown as spheroids, while 
miR199a, miR106b and miR9 are significantly upregulated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Validation of the miRNAarray by RealTimePCR 
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3.2	EXTRACTION	OF	CD133+	FRACTION	IN	GBM	AND	EXPLORATION	OF	MIR	EXPRESSION	
PROFILE	
During two months, we collected freshly excised brain tumors, 
suspectingly GBM, based on imaging and clinical presentation, 
that had been operated at the CHUV. We managed to harvest 
three primary brain tumors during study period. Tumors were cut 
into small pieces, and dissociated to single cell level. Leukocytes 
were removed with negative CD45 selection (magnetic 
microbeads), while red cells were destroyed with an osmotic 
shock. Finally a positive selection was performed for the CD133 
cell surface marker. The negative fraction was kept and named 
hereafter CD133 negative fraction, thereby representing the 
tumor bulk. This positive 133 marker, as discussed previously, 
represents a robust marker for the GSC fraction (72). 
Unfortunately, one primary tumour appeared to be an 
oligodendroglioma on attentive histopathological examination 
and had to be excluded of analysis. Out of the two remaining 
tumours, one GBM did not provide a sufficient output of live cells 
that withstood the entire process, leaving us with only one 
sample to analyze. 
On that specimen, a qPCR was performed in the perspective of 
comparing miRs expression profile between CD133+ and 
CD133- fractions in primary GBM and correlating it with the in 
vitro sphere-adherent culture conditions. A satisfactory 
concordance exists in the expression pattern between the 
primary tumor (CD133 positive vs. negative fraction) and the 
three primary cell lines grown either as spheres or adherent cells. 
Taken together, these results suggest that the sphere and 
adherent culture represent a robust model to study miRs in vitro, 
which reflects the in vivo expression profile of CD133+ vs. 
CD133- fractions, respectively. Although, it must be mentioned 
that these results are difficult to generalize based on a single 
freshly sorted tumour, and would require additional samples to 
confirm these observations.  
 
 
	
Figure 8: Essential steps in 
extraction of the CD133+ 
fraction from a freshly excised 
tumor  	
Figure 9: Validation of CD133+ vs. CD133- fraction miR 
expression profile 	
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3.3	OVEREXPRESSION	OF	MIR21	IN	GSC	
Our work allowed us to identify miRs differentially expressed between distinct cellular states in 
GBM, both in vivo and in vitro. To address the functional relevance of these observations, we re-
expressed one of the top downregulated miR in GSC. Although, miR21 was previously 
characterized as an oncomiR (75), the fact that it was strongly downregulated in GSC raised the 
question whether it may specifically silence stem-cell programs. Therefore, we performed 
lentiviral-mediated overexpression of miR21 in one batch of primary glioma stem cells (BT4) with 
miR21 precursor. MiR precursors are usually expressed rather than mature miRs, as they are 
more stable and subject to maturation that occurs for endogeneous miRs. This plasmid also 
contains a green fluorescent protein (GFP) that allows visual control of infection and a puromycin 
resistance gene for selection of infected cells. 3.3.1	MICROSCOPIC	EXAMINATIONS	
 
 
Figure 10: Gliospheres (BT4 line) infected with pre-miR21(left) or Scrambled-control (Scr-ctrl) (right) 
lentivirus. Upper panel : GFP fluorescence. Lower panel : white light. Pictures were taken after selection 
with puromycin  
Infection efficacy was tested by qPCR, showing about 
2.5 fold upregulation of miR21- compared to Scr-ctrl-
infected cells, consequently validating the efficiency of 
our tools (Figure 10). Additionally, we tested the 
modification of expression of an unrelated and non-
differentially expressed miR, namely miR128, to show 
the specificity of our infection. Moderate virus titer was 
used to achieve an overexpression that was in the 
physiological range of expression observed in adherent 
cells. 
Figure 11: qPCR of miR21 and miR128 on BT4 spheres 
infected with mir21 precursor or Scr-ctrl  
	 20	
3.3.2	GSC	OVEREXPRESSING	MIR21	-	CLONOGENICITY	
After having confirmed efficiency of miR21 re-expression in gliospheres (BT4), we performed 
some functional assays comparing the overexpressing cells vs. Scr-ctrl. First, we studied the 
clonogenic capacity of the spheres.. A clonogenic assay is a method that evaluates the self-
renewal properties of CSCs by assessment of sphere formation at low density of cell seeding. We 
noticed no significant change in sphere formation capacity between miR21-infected cells 
compared to Scr-ctrl. These results suggest that reexpression of miR21 alone is not able to impair 
the self-renewal properties of GSC. 
  
Figure 12: Clonogenic assay of gliospheres infected with miR21 vs. Scr-ctrl lentivirus 
 3.3.3	GSC	OVEREXPRESSING	MIR21	-	PROLIFERATION	ASSAY	
We evaluated whether there was any change in proliferation rates between pre-miR21-infected 
cells and Scr-ctrl. A BRDU (5’bromo-2’uridine) proliferation assay revealed no significant 
difference between the two conditions: suggesting that miR21 is not involved in proliferation 
control of glioma stem cells.   
 
Figure 13: Proliferation assay of pre-miR21 lentivirus 
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4.	DISCUSSION		
4.1	CHARACTERISING	MIR	EXPRESSION	PROFILES	IN	VIVO	AND	IN	VITRO	
Our study determined via qPCR and microRNAarray a general panel of miRs differentially 
expressed in GSC and their differentiated counterparts in vitro, whose trend was then confirmed 
via RealTime PCR in vivo. In both settings, miR21 turned out significantly downregulated in glioma 
stem-like cells compared to differentiated cells. All in all, these results suggest that in vitro the 
sphere and adherent culture conditions stand as a relatively genuine reflection of miRs in vivo, 
which are recognizable with CD133+ versus CD133- surface markers respectively. Obviously, 
additional freshly excised GBM samples are necessary to affirm this statement. 
Even though we observe the same tendency in both frameworks, it should not be forgotten that 
we are manipulating models, which are not entirely representative of the in vivo complexity of 
GBM. 
• First of all, the tumor type of origin, for either the cell lines or the in vivo model, has to be 
considered: are we facing a recurrence or a primary GBM? What kind of subtype is it 
(classical, mesenchymal, neural, proneural)? Has the tumor already been treated with 
either chemo or radiotherapy? All these factors can influence the quantity of GSC but also 
the features they are showing — especially regarding their expression panels. The tumour 
that was harvested at CHUV was a recurrence of GBM. GBM cell lines that were used join 
the proneural subtype. As described in the introduction, all these different expression 
profiles in all these settings still remain to be established ; 
• Secondly, GBM has been described as heterogenous inter- (20) and intratumorally 
(22)(21), which, evidently, is of influence when studying only a few samples and data 
derived from a collection of cells; 
• Moreover, either when being excised from the brain environment or having been in culture 
for several cycles, changes take place in cells on a transcriptome basis, but even more 
likely on a epigenetic basis: reprogramming may occur and miRs expression profiles may 
adapt to the new environment (76); 
• Finally, GSC’s identification is not entirely established yet. Even though, there exists a 
clear consensus towards CD133 surface marker as an identification tool for GSC, CD133- 
cells have sometimes shown stem cell properties as well (14); 
Since change in GBM occurs in space and time, improvements can be done by:  
• Fine-tuning subtypes characterisation, especially regarding miRs (18); 
• Developing systems for multiple biopsy execution through time and space (14); 
• Bettering biomarkers’ specificity: via radiological imaging or repeated blood samples for 
circulating biomarkers (14); 
• Precisely describing or finding a single, instead of a combination of identification marker 
for GSC (77); 
In the literature, only one publication was found to study the same subject in vitro. It is showing 
similar results: downregulation of miR21, miR29a, miR221 and miR222 and upregulation of 
miR106b in GSC compared to differentiated GBM cells (78). It is of note that Wu et al. (79) agreed 
on the same system representing spheres in vitro, as a CD133+ population in vivo, which stands 
as a model for GSC. 
In vivo studies display concordant observations towards the following miRs: downregulation of 
miR21, miR9, miR340 and miR221 (79) and upregulation of miR221(80) and miR106b (80) (50) in 
the CD133+ fraction. Only Wu et al. (79) disagreed on miR106b, which they observed as 
downregulated in GSC. 
All in all, as noticed, many researchers agree on performing high-throughput analysis since, as 
Melo et al. would describe, entire miRnome and not only a single oncogenic or tumour-suppresive 
miRs is disrupted in cancer (51). 
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4.2	FUNCTIONALITY	OF	MIR21	
After having overexpressed miR21 via infection and selected cells for their puromycin resistance, 
we observed some slight phenotypic differences under the microscope. Infected cells, with either 
Scr-ctrl or miR21, expressed GFP, which allowed improved visualisation. Under microscopic 
examination, mir21-infected cells, as opposed to controls, did not 100% manage to rebuild 
spheres after five days and some of them remained as aggregates. Yet, the results did not show a 
drastic contrast. When extracting RNA from these modified cells and performing a qPCR, we 
confirmed the infection’s efficacy and validated the differentially expressed miRs profile.  
From a clonogenicity and proliferation point of view, we did not observe a statistically relevant 
divergence between these two populations, despite detecting a slight trend towards self-renewal 
decrease and proliferation enhancement in miR21-infected cells. In order to improve these 
results, additional sampling is necessary to reduce error bars. Seemingly, miR21 might be 
partially involved in tumorigenicity, however this specific miR is probably not the only one 
responsible for initiating tumours. Therefore, studying other miRs, in conjuncture with miR21, 
using a similar approach might be of interest in establishing involvements of miRs in 
tumorigenicity of GSC. 
According to literature, miR21 has been described as one of the main oncogenes in GBM and its 
presence is inversely correlated to survival (66). Noticeably, this evidence is derived from datasets 
obtained from tumor-bulks, which do not reflect the specificities of the different cell population 
observed in intra-tumoral heterogeneity of GBM, letting us hypothesize that miR21 state is cell-
dependent within GBM. Via the p53 network, TGF-beta and mitochondrial apoptosis tumor 
suppressors genes, miR21 increases apoptosis and cell cycles arrest and represses tumor growth 
(70). When being depleted, it activates caspases, which increase apoptosis as well  (63). Between 
GBM and normal brain tissue, its oncomiR status has been well established (75) and its level of 
upregulation in tumor tissue is correlated with progression of gliomas towards more aggressive 
grade (81). Despite being linked to glioma angiogenesis, miR21-positive tumor cells do not 
display stem cell features; in concordance with our results, expression of stem cell markers, such 
as CD133, was not correlated to miR21 (82). 
Apropos of clonogenicity, no studies have been performed in regards to miR21 and GSC; only 
miR135b (83) and miR130b (84) have been described to affect clonogenic abilities. Referring to 
proliferation, miR21 has been depicted to improve proliferation in vitro and tumor size in vivo 
when being overexpressed in all GBM cells (66). By directly downregulating FASLG protein 
expression, overexpression of miR21 in GBM (and GSC, which does not match our results) has 
been shown to regulate GSC apoptosis and enhance GSC proliferation (85). 
Altogether, seeing the amount of studies in the matter, these observations indicate that the 
therapeutic benefit of miR21 modulation is still debatable (62).  
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5.	CONCLUSION	AND	FURTHER	DEVELOPMENTS		
In summary, miR21 is downregulated in cancer cells that display stem-cell traits compared to 
differentiated GBM cells in vitro as well as in vivo. We hypothesized that re-expression of miR21 
in GSC may silence stem-cell programs and reduce their tumorigenic properties. Our in vitro 
observations failed to reveal any difference in clonogenic and proliferation capacity of miR21 
overexpressing GSC.  
Since miR21 is downregulated in GSC (the tumorigenic fraction of GBM), despite being an 
established upregulated oncomiR in the tumor bulk, this work suggests that miR21 implication in 
GBM development does not occur via GSC. 
The following steps of this study would include enhanced description of miR21 overexpressing 
GSC in order to evaluate their tumor-initiating capacity, which remains one of the hallmarks of 
GSC. Additional functional assays such as, in vitro, apoptosis evaluation and in vivo studies by 
intracranial injection in NOD-SCID common γKO mice would complete the assessment. 
Identification of precise mRNA targets of miR21 by microArray and then qPCR for confirmation is 
the subsequent stage. Supplemental proteinomics studies via Western Blot and qPCR will add 
the final touch to the project.  
Now that miR21 is starting to be established as a diagnostic and pronostic tool, this type of 
project will allow us to identify distinct targets for radical treatment and have a major impact on 
clinical outcome, particularly regarding recurrence. 
 
6.	METHODS		
6.1	IDENTIFICATION	OF	MIRS	EXPRESSED	IN	PRIMARY	GLIOBLASTOMA	CELL	LINES	IN	VITRO		6.1.1	CELL	CULTURE		
Surgical specimens of GBM tumours were collected at Massachusetts General Hospital following 
approval by the institutional review board (IRB). Glioma stem cells used in this study have been 
thoroughly characterized in previous work (86)(87)(88). GSC (BT4, 8 & 11) were grown in 
Neurobasal medium (Invitrogen) supplemented with L-glutamine (Glutamax, Gibco), B27 
supplement (Invitrogen), N2 supplement (Invitrogen), antibiotics (PenStrep 1%), 20 ng/mL 
recombinant human EGF (R&D Systems), 20 ng/ml recombinant human FGF2 (R&D Systems). 
Spheres were mechanically dissociated and diluted once they reached a diameter of 100 um. At 
each passage a fraction of the cells was frozen to maintain a low passage source of cells for 
experimental procedures (<25). GSC differentiation was induced by addition of 10% FCS (+ 
NEAA) and withdrawal of growth factors for 7 days on 100ug/mL poly-D-lysine (ref. P7280, Sigma) 
and 15ug/mL laminin (ref. L2020, Sigma) coated plates. Cells were subsequently grown and 
expanded as adherent monolayers.  6.1.2	RNA	EXTRACTION,	CDNA	SYNTHESIS	AND	QUANTITATVE	PCR		
RNA extraction was performed using miRCURY RNA isolation kit (Exiqon) in conjunction with 
DNAse treatment (Qiagen). 500ng of RNA were reverse-transcribed using M-MLV (Promega) to 
generate cDNA. qRT-PCR was performed with Power SYBR Green mastermix (Applied 
Biosystems). Each PCR reaction was performed in triplicate and normalized to endogeneous 
controls PPIA and 18S (ThermoFisherScientific). For microRNA-qRT-PCR, 50ng of template RNA 
were retro-transcribed using a universal cDNA synthesis kit (Exiqon). qRT-PCR was done in 
triplicate with primers annealing to mature miR (microRNA LNA PCR primer sets, Exiqon) and 
relative quantification of each target was normalized to RNU5G and SNORD49a (Exiqon).  
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6.1.3	MIRNA	ARRAY		
Probe intensities provided by the facility were analyzed using limma. Log-transformed values 
were normalized between arrays using cyclic-loess. For hierarchical-clustering, the 20 miRs with 
highest fold-changes were clustered by complete-linkage using base R functions. 
 
6.2	EXTRACTION	OF	CD133+	FRACTION	IN	GBM	AND	EXPLORATION	OF	MIR	EXPRESSION	
PROFILE	6.2.1	CD133	EXTRACTION	
Surgical specimens were harvested at the CHUV Hospital, Lausanne. Among the three primary 
tumors collected, only one sample had matter for analysis. MACS Miltenyi Biotec kits were used 
to first dissociate brain tumors with papaïne, remove dead cells and white blood cells (using 
CD45 microbeads for WBCs) and finally seperate CD133 + and – fractions for analysis. Red blood 
cells were osmotically exploded applying ACK after the dissociation stage. Every step was 
thoroughly done according to the manufacturers instructions. After GSC selection, RNA 
extraction and qPCR were performed as described above. 
 
6.3	OVEREXPRESSION	OF	MIR21	IN	GSC	6.3.1	LENTIVIRAL	INFECTIONS,	OVEREXPRESSION	PLASMIDS	
Infection of primary GBMs was performed using lentiviruses. For viral production, HEK 293T 
packaging cells were transfected with the plasmid of interest, PMD2G and PCMVdR8 using 
FuGene HD (Promega). Virus containing media was harvested after 72 hours, 0.45um filtered 
(Millipore) and ultracentrifuged for 2 hours at 4°C, at 19’500 RPM using a SW28 rotor (Beckman 
Coulter). Supernatants were decanted and pellets were re-suspended by gentle pipetting. GBM 
cells were infected for 16 hours and selection was added 48 hours later for four days (Puromycin, 
2mg/mL). Cells were immediately used for experiments. For overexpression experiments, miR21 
was amplified using plasmids incoding pre-miR21 sequences (controlled by a CMV promoter), 
puromycin resistance cassette and GFP for luminescent control. The plasmid’s sequence is 
verified and manufactured by BioCAT Laboratories. Plasmid purification was achieved using 
JetStar kit (Genomed) according to the manufacturers procedure. 
 6.3.2	GSC	OVEREXPRESSING	MIR21	-	CLONOGENICITY	
Glioma stem cells infected with Scr-ctrl or miR21 were mechanically dissociated and plated at 
single cell density in 96-well low adherence plates. Sphere number was assessed four weeks later 
by imaging. Each clonogenic assay was performed in triplicate. 
 6.3.3	GSC	OVEREXPRESSING	MIR21	-	PROLIFERATION	ASSAY	
Cell Proliferation ELISA (BrdU) protocols by Roche were applied to establish proliferation. Glioma 
stem cells infected with Scr-ctrl vs. miR21 were spread, after careful dissociation, by 25'000 cells 
per wale in 5 replicates per plate in four 96-wales plates (not including controls). Each 12h, one of 
the 96-wales plate had BRDU (5-bromo-2’-deoxyuridine) added to cells at a 1:1'000 
concentration. After overnight incubation, and supernatant elimination, each plate was heated at 
60°C for 1h and then stored at 4°C in aluminium in the wait of the other plates to proliferate until 
the desired time. Revelation was unveiled according to the manufacturers recommendations 
(using FixDenat and anti-BrdU solutions) and absorbance was measured a 492 nm with a 
luminometer. 
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APPENDIX		
Figure 14: The 2007 WHO Classification of Tumours of the Central Nervous System. Reproduced from (23) 
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